ASH News Daily - Monday, December 12, 2011 - (Page A-16)
Page A–16
®
ASH NEWS DAILY
Congratulations to winners of
the National Marrow Donor Program®
Awards for Best ASH Abstracts
In celebration of the National Marrow Donor Program’s (NMDP)
25th
anniversary and facilitation of 50,000 unrelated donor
hematopoietic cell transplants, NMDP has partnered with ASH
to provide awards, totaling $25,000, to the highest-scoring
abstracts in 10 categories at the 2011 ASH Annual Meeting.
View a short video about
progress in transplant.
Scan this code or
view online at:
marrow.org/ASH
Scan this code
BMT
If Transplant is Dying, It Sure
Is Enjoying Its Final Days
By Michael r. BiShop, Md
“
T
to access video
Award winners:
Acute Lymphoblastic Leukemia—Biology & Pathophysiology
Mark Y. Chiang, MD, PhD, University of Michigan
Abstract #75
Acute Myeloid Leukemia—Biology & Pathophysiology
Tanja A. Gruber, MD, PhD, St. Jude Children’s Research Hospital
Abstract #757
Bone Marrow Failure
Pekka Jaako, Lund University
Abstract #727
Clinical Allogeneic Transplantation: Acute and Chronic GVHD,
Immune Reconstitution
David Jacobsohn, MD, Children’s National Medical Center
Abstract #151
Clinical Allogeneic Transplantation: Conditioning Regimens,
Engraftment, and Acute Transplant Toxicities
Riccardo Saccardi, MD, Eurocord Registry
Abstract #650
Clinical Allogeneic and Autologous Transplantation:
Late Complications and Approaches to Disease Recurrence
Saro Armenian, DO, MPH, City of Hope
Abstract #330
Clinical Allogeneic and Autologous Transplantation: Results
Claudio Anasetti, MD, H. Lee Moffitt Cancer Center
& Research Institute
Abstract #1
Health Services and Outcomes Research
Can-Lan Sun, PhD, City of Hope
Abstract #841
Myelodysplastic Syndromes
Luca Malcovati, Fondazione IRCCS Policlinico San Matteo
& University of Pavia
Abstract #3
Non-Hodgkin Lymphoma—Biology, excluding Therapy
Jens Lohr, MD, PhD, Dana-Farber Cancer Institute
Abstract #259
Our achievements change lives. Our people inspire cures.
Visit the NMDP booth (#1621)
to join in the celebration.
At Millennium: The Takeda Oncology Company located in Cambridge, MA, “We Aspire to Cure Cancer”.
As a leading biopharmaceutical company focused on oncology, Millennium combines the agility, ideals and
camaraderie of a start-up with the resources of Japan’s largest pharmaceutical company. The result is an
entrepreneurial culture where the priorities are quality science and making a difference in patients’ lives
and the communities we serve.
Our people share a commitment to innovation in an environment where individual contributions are not
just valued, but rewarded. Here you’ll enjoy outstanding benefits, a friendly, respectful atmosphere and a
culture that promotes flexibility between your personal and professional life. Join Millennium and improve
the lives of others while living yours to the fullest.
To view our current career opportunities and apply online,
visit: joinmillennium.com/37.
©2011 Millennium Pharmaceuticals, Inc. All rights reserved.
5
he report of my death was an
exaggeration” – Mark Twain,
1897.
This was Mr. Twain’s exact re-
sponse to a report in the New York
Journal, which ran a story of his
death, although it was actually
Twain’s cousin. This would not be
the last time that Twain would be
prematurely declared dead, as the
New York Times ran a story of him
being lost at sea in 1907 (his boat
was actually delayed by fog). This is
how some feel about hematopoietic
stem cell transplantation (HSCT),
as it has been said that transplant is
“dead.” If it’s dead, or even dying, it
sure is enjoying a prolonged death,
as evidenced by the breath of the
advances that will be shared today
in 14, count them, 14 different Oral
sessions that are directly related to
HSCT. For those of you who are interested
in transplantation, you will
not be disappointed in the choices,
which run from 7:00 in the morning
all the way through to a final session
that starts at 6:15 tonight. You
are going to have to plan your day
carefully, as there are a number of
presentations with great scientific
and clinical relevance.
Dr. Annamaria Brioli, represent-
ing the GIMEMA Italian Myeloma
Network, will present results of an
analysis of the effects of induction
therapy with bortezomib, thalidomide,
and dexamethasone upon the
collection and engraftment potential
of peripheral blood stem cells
in myeloma patents in the first session
of Cell Collection and Processing
in the Elizabeth Ballroom DE,
Manchester Grand Hyatt San Diego
at 7:00 a.m. At 8:00 a.m., during the
first experimental transplantation
session, which will be held in Douglas
Pavilion A at the Manchester
Grand Hyatt San Diego, Dr. Cristiana
Carniti will share her group’s results
on the use of circulating micro
RNAs as a tool for the early diagnosis
of acute GVHD. To further muddy
the water on the use of peripheral
blood or bone marrow in allogeneic
HSCT, Dr. Marco Mielcarek, representing
his colleagues from Seattle,
Stanford, and the City of Hope, will
present long-term, follow-up results
on their randomized trial of blood
versus marrow, which was initially
published in the New England Journal
of Medicine in 2001. These results
will be shared at 7:00 a.m. during the
Clinical Allogeneic Transplantation
Oral session in Douglas Pavilion D,
Manchester Grand Hyatt San Diego.
Next are the mid-morning ses-
sions that will include updated results
on the use of defibrotide in the
treatment of hepatic veno-occlusive
disease, presented by Dr. Paul
Richardson at 10:30 a.m. during the
Clinical Allogeneic Transplantation:
Conditioning Regimens, Engraftment,
and Acute Transplant
Toxicities session in Douglas Pavilion
B, Manchester Grand Hyatt San
Diego. There will be several presentations
on the use of transplantation
in AML during the Clinical
Allogeneic and Autologous Transplantation
session in Douglas Pavilion
D, Manchester Grand Hyatt
San Diego.
Following lunch and the Ernest
Beutler Lecture, the sessions pick up
again. One of the highlights of the afternoon
will be the presentation of the
results of the randomized phase III
Trial of BEAM plus 131
iodine-Tositumomab
versus BEAM plus rituximab
»» TRANSPLANT Page A-19
Image: colored scanning electron
micrograph (SEM) of a lung cancer cell.
Monday, December 12, 2011
NMDP_Ad_ASH_News Daily_V4.indd 1
#####; NOV 2011
9/30/11 2:47 PM
Table of Contents for the Digital Edition of ASH News Daily - Monday, December 12, 2011
ASH News Daily - Monday, December 12, 2011
https://www.nxtbookmedia.com